Zenocutuzumab is the first FDA-approved treatment for NRG1-positive NSCLC and pancreatic adenocarcinoma. The eNRGy study demonstrated a 33% overall response rate in NSCLC and 40% in pancreatic ...
Pancreatic ductal adenocarcinoma (PDA) is the most common type of pancreatic cancer, accounting for at least 90% of cases. Doctors may use the terms PDA and pancreatic cancer interchangeably since ...
An interview with Dr. AloK Khorana from Cleveland Clinic on "Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update." This guideline update adds another treatment ...
The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has ...
Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. Shares of the ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in ...
The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback